MCID: ANX002
MIFTS: 67

Anxiety Disorder malady

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Anxiety Disorder

Aliases & Descriptions for Anxiety Disorder:

Name: Anxiety Disorder 12 14
Anxiety 12 29 41 69
Anxiety Disorders 52 42 69
Anxiety State 12 69
Anxiety Neurosis 69

Classifications:



External Ids:

Disease Ontology 12 DOID:2030
ICD10 33 F41.9 F41.8
ICD9CM 35 300.09
MeSH 42 D001008
NCIt 47 C2878

Summaries for Anxiety Disorder

MedlinePlus : 41 fear and anxiety are part of life. you may feel anxious before you take a test or walk down a dark street. this kind of anxiety is useful - it can make you more alert or careful. it usually ends soon after you are out of the situation that caused it. but for millions of people in the united states, the anxiety does not go away, and gets worse over time. they may have chest pains or nightmares. they may even be afraid to leave home. these people have anxiety disorders. types include panic disorder obsessive-compulsive disorder post-traumatic stress disorder phobias generalized anxiety disorder treatment can involve medicines, therapy or both. nih: national institute of mental health

MalaCards based summary : Anxiety Disorder, also known as anxiety, is related to antisocial personality disorder and schizophrenia, and has symptoms including nervousness, agitation and feeling tense. An important gene associated with Anxiety Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian entrainment. The drugs Ethanol and Norepinephrine have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and brain, and related phenotypes are Decreased viability and behavior/neurological

Disease Ontology : 12 A cognitive disorder that involves an excessive, irrational dread of everyday situations.

Wikipedia : 71 Anxiety disorders are a group of mental disorders characterized by feelings of anxiety and fear. Anxiety... more...

Related Diseases for Anxiety Disorder

Diseases related to Anxiety Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 181)
id Related Disease Score Top Affiliating Genes
1 antisocial personality disorder 30.1 HTR1A HTR2A
2 schizophrenia 29.9 BDNF CCK COMT CYP2D6 DRD2 HTR1A
3 hypoglycemia 29.4 BDNF CRH DRD2 SLC6A4
4 personality disorder 29.0 BDNF CCK COMT CRH CYP2D6 DRD2
5 autism spectrum disorder 29.0 BDNF CCK COMT OXT SLC6A2 SLC6A3
6 generalized anxiety disorder 12.5
7 separation anxiety disorder 12.4
8 phobic disorder 11.6
9 panic disorder 11.6
10 social phobia 11.5
11 agoraphobia 11.3
12 obsessive-compulsive disorder 11.2
13 phobia, specific 11.2
14 eating disorder 11.1
15 bipolar disorder 11.0
16 hypochondriasis 11.0
17 post-traumatic stress disorder 10.9
18 neurotic disorder 10.9
19 elective mutism 10.6
20 acute stress disorder 10.6
21 aids - neurological complications 10.6
22 neurogenic bladder 10.3 HTR2A MAOA SLC6A4
23 dry eye syndrome 10.3 HTR1A HTR2A SLC6A4
24 nephronophthisis 13 10.3 COMT HTR2A SLC6A4
25 euthyroid sick syndrome 10.3 DRD2 HTR2A SLC6A4
26 adult brainstem astrocytoma 10.3 HTR1A MAOA SLC6A4
27 intracranial cavernous angioma 10.3 DRD2 SLC6A3 SLC6A4
28 allergic hypersensitivity disease 10.3 DRD2 HTR1A HTR2A
29 vascular cancer 10.3 DRD2 HTR1A HTR2A
30 urea cycle disorder 10.2 BDNF COMT DRD2
31 waardenburg's syndrome 10.2 DRD2 HTR1A HTR2A SLC6A4
32 splenic abscess 10.2 DRD2 HTR2A SLC6A3 SLC6A4
33 apperceptive agnosia 10.2 COMT DRD2 HTR1A SLC6A4
34 kidney pelvis papillary carcinoma 10.2 HTR1A MAOA SLC6A2 SLC6A4
35 polyneuropathy 10.2 HTR1A HTR2A
36 breast reconstruction 10.2 BDNF COMT DRD2
37 transmitted_by 10.2 DRD2 SLC6A3 SLC6A4
38 anodontia 10.2 HTR1A HTR3A SLC6A3 SLC6A4
39 conjunctival pigmentation 10.2 CRH MAOA SLC6A4
40 luxation of globe 10.2 HTR1A NPY SLC6A4
41 alopecia 10.2 BDNF DRD2 SLC6A4
42 siberian tick typhus 10.2 BDNF HTR1A HTR3A TSPO
43 myopathy, distal, with early respiratory failure, autosomal dominant 10.2 COMT SLC6A3 TPH1
44 rectosigmoid junction neoplasm 10.2 DRD2 SLC6A3 TPH2
45 abnormal pupillary function 10.2 HTR1A HTR3A
46 mastitis 10.2 OXT SLC6A3 TSPO
47 pyromania 10.2 DRD2 HTR2A MAOA SLC6A3 SLC6A4
48 primary angle-closure glaucoma 10.2 BDNF COMT HTR1A HTR2A SLC6A4
49 strongyloidiasis 10.2 COMT DRD2 MAOA SLC6A3 SLC6A4
50 aortic valve disease 2 10.2 COMT DRD2 HTR3A SLC6A3

Comorbidity relations with Anxiety Disorder via Phenotypic Disease Network (PDN): (show top 50) (show all 79)


Acute Cor Pulmonale Acute Cystitis
Acute Stress Disorder Adjustment Disorder
Allergic Rhinitis Atrophic Gastritis
Atypical Depressive Disorder Basilar Artery Insufficiency
Benign Essential Hypertension Benign Paroxysmal Positional Nystagmus
Borderline Personality Disorder Bronchiectasis
Bronchitis Bronchopneumonia
Cerebrovascular Disease Chronic Myocardial Ischemia
Chronic Pulmonary Heart Disease Chronic Rhinitis
Conversion Disorder Deficiency Anemia
Delusional Disorder Dependent Personality Disorder
Dyskinesia of Esophagus Dysthymic Disorder
Esophagitis Familial Atrial Fibrillation
First-Degree Atrioventricular Block Gastroesophageal Reflux
Generalized Anxiety Disorder Generalized Atherosclerosis
Heart Disease Histrionic Personality Disorder
Hyperlipoproteinemia Type Iv Hypertension, Essential
Hypertensive Encephalopathy Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis
Hypochondriasis Hypothyroidism
Intermediate Coronary Syndrome Intestinal Obstruction
Iron Deficiency Anemia Irritable Bowel Syndrome
Ischemic Heart Disease Labyrinthitis
Malignant Essential Hypertension Meniere's Disease
Migraine with or Without Aura 1 Mitral Valve Disease
Mood Disorder Narcissistic Personality Disorder

Graphical network of the top 20 diseases related to Anxiety Disorder:



Diseases related to Anxiety Disorder

Symptoms & Phenotypes for Anxiety Disorder

UMLS symptoms related to Anxiety Disorder:


nervousness, agitation, feeling tense, mental and behavioral signs and symptoms, feeling jittery, sleeplessness

GenomeRNAi Phenotypes related to Anxiety Disorder according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.1 HTR1A HTR3A SLC6A4
2 Decreased viability GR00381-A-3 9.1 HTR1A HTR3A SLC6A4

MGI Mouse Phenotypes related to Anxiety Disorder:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.47 ADCYAP1R1 BDNF CCK COMT CRH CRHR1
2 homeostasis/metabolism MP:0005376 10.36 HTR3A MAOA NPY OXT SLC6A2 SLC6A3
3 growth/size/body region MP:0005378 10.25 ADCYAP1R1 BDNF CRH DRD2 HTR3A NPY
4 endocrine/exocrine gland MP:0005379 10.23 COMT BDNF CCK CRH CRHR1 DRD2
5 cardiovascular system MP:0005385 10.22 TPH2 TSPO COMT CRHR1 DRD2 HTR1A
6 nervous system MP:0003631 10.22 ADCYAP1R1 BDNF CCK COMT CRH CRHR1
7 integument MP:0010771 10.07 CRH DRD2 HTR3A OXT SLC6A2 SLC6A3
8 adipose tissue MP:0005375 9.99 CRH DRD2 NPY OXT TPH1 TPH2
9 no phenotypic analysis MP:0003012 9.86 ADCYAP1R1 BDNF CCK CRH CRHR1 DRD2
10 normal MP:0002873 9.85 ADCYAP1R1 BDNF CRH CRHR1 DRD2 NPY
11 respiratory system MP:0005388 9.5 CRH CRHR1 DRD2 TPH1 TPH2 BDNF
12 taste/olfaction MP:0005394 8.92 BDNF DRD2 SLC6A3 TPH2

Drugs & Therapeutics for Anxiety Disorder

Drugs for Anxiety Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 955)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 64-17-5 702
2
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-41-2 439260
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
4
Clonidine Approved Phase 4,Phase 2,Phase 3 4205-90-7 2803
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3 50-02-2 5743
6
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 60142-96-3 3446
7
Carbamazepine Approved, Investigational Phase 4,Phase 3,Phase 2 298-46-4 2554
8
Heroin Approved, Illicit Phase 4,Phase 2,Phase 1 561-27-3 5462328
9
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 54-11-5 942 89594
10
Diazepam Approved, Illicit, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1 439-14-5 3016
11
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-28-2 5757 53477783
12
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
13
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
14
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59467-70-8 4192
15
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
16
Tenofovir Approved, Investigational Phase 4 147127-20-6 464205
17
Morphine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 57-27-2 5288826
18
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1 103-90-2 1983
19
Ibuprofen Approved Phase 4,Phase 3,Phase 2 15687-27-1 3672
20
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1 99-66-1 3121
21 Moxonidine Approved Phase 4 75438-57-2 4810
22
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-84-3 187
23
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2 19982-08-2 4054
24
Rocuronium Approved Phase 4,Phase 3 119302-91-9, 143558-00-3 441290
25
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 75614-87-8, 51-45-6 774
26
Propranolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 525-66-6 4946
27
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-23-7 5754 657311
28
Buspirone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 36505-84-7 2477
29
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 132539-06-1 4585
30
Drospirenone Approved Phase 4 67392-87-4 68873
31
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1 34841-39-9, 34911-55-2 444
32
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
33
Mianserin Approved Phase 4,Phase 3,Phase 2 24219-97-4 4184
34
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 113-45-1 4158
35
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 76631-46-4, 113775-47-6 68602 5311068 56032
36
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 54910-89-3 3386
37
Dronabinol Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1 1972-08-3 16078 2978
38
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 137-58-6 3676
39
Oxytocin Approved, Vet_approved Phase 4,Phase 1,Phase 2,Early Phase 1 50-56-6 439302 53477758
40
Remifentanil Approved Phase 4 132875-61-7 60815
41
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2180-92-9, 38396-39-3 2474
42
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 59729-33-8 2771
43
Fluvoxamine Approved, Investigational Phase 4,Phase 3,Phase 1 54739-18-3 3404 5324346
44
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 6740-88-1 3821
45
Chlordiazepoxide Approved, Illicit Phase 4 58-25-3 2712
46
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3 2078-54-8 4943
47
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61869-08-7 43815
48
Alprazolam Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 28981-97-7 2118
49
Mirtazapine Approved Phase 4,Phase 3,Phase 2,Phase 1 85650-52-8, 61337-67-5 4205
50
Clomipramine Approved, Vet_approved Phase 4,Phase 3,Phase 2 303-49-1 2801

Interventional clinical trials:

(show top 50) (show all 5000)
id Name Status NCT ID Phase
1 Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder Unknown status NCT00662259 Phase 4
2 Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD Unknown status NCT00579280 Phase 4
3 Perioperative Pregabalin Use, Rehabilitation, Pain Outcomes and Anxiety Following Hip Surgery Unknown status NCT00762099 Phase 4
4 The Effect of Sihogayonggolmoryeo-tang on the Anxiety of Hwa-byung Unknown status NCT01362114 Phase 4
5 Preoperative Anxiety and Postoperative Pain in Children Unknown status NCT00643032 Phase 4
6 Effect of Music Over the Tolerance to Colonoscopy. Unknown status NCT01285284 Phase 4
7 Assessment of the Effectiveness of a Program of Preparation to Pregnancy and Delivery Unknown status NCT01155804 Phase 4
8 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4
9 Effect of Additive Lorazepam on Patient Satisfaction as a Premedication in Diagnostic Flexible Bronchoscopy Unknown status NCT01121055 Phase 4
10 Comparison of Wound Bed Establishment in Facial Burns Unknown status NCT01668030 Phase 4
11 Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients Unknown status NCT02213016 Phase 4
12 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
13 Oral Midazolam for Sedation in Esophagogastroduodenoscopy(EGD) Unknown status NCT01990937 Phase 4
14 Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects Unknown status NCT02042001 Phase 4
15 Add on Study on Δ9-THC Treatment for Posttraumatic Stress Disorders (PTSD) Unknown status NCT00965809 Phase 4
16 Clinical Trial to Evaluate the Efficacy of FITOGYN Versus Placebo on the Vasomotor Symptomatology Associated With Menopause Unknown status NCT01116310 Phase 4
17 The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery Unknown status NCT01606111 Phase 4
18 Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity Unknown status NCT01180231 Phase 4
19 DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4
20 Effect Site Controlled, Reaction Time Safeguarded, Patient Maintained Sedation With Propofol in Anxious Patients Unknown status NCT00355693 Phase 4
21 Efficacy Study of Escitalopram for Depression in Patients With Diabetes Unknown status NCT00650897 Phase 4
22 Prevention of Posttraumatic Stress Disorder (PTSD) With Diazepam Unknown status NCT01221883 Phase 4
23 Eyegaze Systems for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943656 Phase 4
24 Customized Acoustic Stimulation for Long Term Medical Benefit for the Relief of Tinnitus and Hyperacusis Unknown status NCT00730834 Phase 4
25 Clinical Trial to Evaluate the Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children Unknown status NCT00770627 Phase 4
26 Effects of Dexmedetomidine on Postoperative Cognitive Dysfunction During One-lung Ventilation in Elder Patients Unknown status NCT02134093 Phase 4
27 Impact of Probiotic Preparation VSL#3 on Infants Colics Unknown status NCT01869426 Phase 4
28 The Use of Oral N-Acetyl Cysteine for the Treatment of Chronic Sinonasal Symptoms Unknown status NCT00866866 Phase 4
29 Climacteric Clinical Trial : the Use of Complementary Therapy and Hormonal Replacement Unknown status NCT00617500 Phase 4
30 Methylphenidate in Healthy Young Adults Unknown status NCT00815841 Phase 4
31 Study of the Safety and Efficacy of Botox in Bruxism Unknown status NCT00908050 Phase 4
32 Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD) Unknown status NCT01517711 Phase 4
33 Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled Release Unknown status NCT00492414 Phase 4
34 Creative Therapy to Affect Stroke Outcomes Unknown status NCT01455155 Phase 4
35 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4
36 Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD) Unknown status NCT00743834 Phase 4
37 Olanzapine Versus Lithium in the Treatment of Acute Depression in Patients With Bipolar II or Bipolar Not Otherwise Specified(OL Study) Unknown status NCT02287259 Phase 4
38 Paracervical Block for Pain Control in First Trimester Abortion Unknown status NCT01094366 Phase 4
39 Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy Unknown status NCT00150839 Phase 4
40 Ultrasound Guided Cannulation of Dialysis Fistulas Unknown status NCT01163981 Phase 4
41 Transcranial Magnetic Stimulation for Post-Traumatic Stress Disorder Unknown status NCT00134446 Phase 4
42 Identifying Brain and Genetic Markers of Sertraline Treatment Response in People With Social Anxiety Disorder Completed NCT00872131 Phase 4
43 Use of Alpha-Stim Cranial-electrotherapy Stimulation (CES) in the Treatment of Anxiety Completed NCT01533415 Phase 4
44 Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder Completed NCT00113295 Phase 4
45 A Study of Duloxetine in Elderly Generalized Anxiety Disorder Completed NCT01118780 Phase 4
46 Chamomile Therapy for Generalized Anxiety Completed NCT00645983 Phase 4
47 Quetiapine Augmentation for Primary Anxiety Disorder or Mood Disorders With Co-morbid Anxiety Symptoms Completed NCT00912535 Phase 4
48 Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder Completed NCT00208741 Phase 4
49 Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD) Completed NCT00219349 Phase 4
50 12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder Completed NCT01316302 Phase 4

Search NIH Clinical Center for Anxiety Disorder

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: anxiety disorders

Genetic Tests for Anxiety Disorder

Genetic tests related to Anxiety Disorder:

id Genetic test Affiliating Genes
1 Anxiety 29

Anatomical Context for Anxiety Disorder

MalaCards organs/tissues related to Anxiety Disorder:

39
Heart, Testes, Brain, Amygdala, Cortex, Eye, Prefrontal Cortex

Publications for Anxiety Disorder

Articles related to Anxiety Disorder:

(show top 50) (show all 1357)
id Title Authors Year
1
Predictors of remission from generalized anxiety disorder and major depressive disorder. ( 27863710 )
2017
2
Reduction in Costs after Treating Comorbid Panic Disorder with Agoraphobia and Generalized Anxiety Disorder. ( 28418834 )
2017
3
The relationship of social anxiety disorder symptoms with probable attention deficit hyperactivity disorder in Turkish university students; impact of negative affect and personality traits of neuroticism and extraversion. ( 28460287 )
2017
4
Predicting cognitive behavioral therapy response in social anxiety disorder with anterior cingulate cortex and amygdala during emotion regulation. ( 28462086 )
2017
5
Long noncoding RNAs: New evidence for overlapped pathogenesis between major depressive disorder and generalized anxiety disorder. ( 28529365 )
2017
6
The development and validation of static and adaptive screeners to measure the severity of panic disorder, social anxiety disorder, and obsessive compulsive disorder. ( 28370638 )
2017
7
Combining Metacognitive Strategies with Traditional Cognitive Behavior Therapy in Generalized Anxiety Disorder: A Case Illustration. ( 28515551 )
2017
8
Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: A meta-analysis. ( 28483071 )
2017
9
Altered activation of the ventral striatum under performance-related observation in social anxiety disorder. ( 28464974 )
2017
10
Obsessive-compulsive disorder has a reduced placebo (and antidepressant) response compared to other anxiety disorders: A meta-analysis. ( 28477500 )
2017
11
Feeling safe but appearing anxious: Differential effects of alcohol on anxiety and social performance in individuals with social anxiety disorder. ( 28441522 )
2017
12
Association between Physicians' Adherence to a Pharmacotherapy Guideline and Continuity of Care for Patients with Depression and/or Anxiety Disorder. ( 28510467 )
2017
13
Repetitive transcranial magnetic stimulation of the right dorsal lateral prefrontal cortex in the treatment of generalized anxiety disorder: A randomized, double-blind sham controlled clinical trial. ( 28533148 )
2017
14
Pathways from uncertainty to anxiety: An evaluation of a hierarchical model of trait and disorder-specific intolerance of uncertainty on anxiety disorder symptoms. ( 27984787 )
2017
15
Modification of the medical exclusion criterion in DSM-5 social anxiety disorder: Comorbid obesity as an example. ( 28064111 )
2017
16
Client Retrospective Accounts of Corrective Experiences in Motivational Interviewing Integrated With Cognitive Behavioral Therapy for Generalized Anxiety Disorder. ( 28072459 )
2017
17
The influence of attention biases and adult attachment style on treatment outcome for adults with social anxiety disorder. ( 28441619 )
2017
18
Sex differences in the association between area deprivation and generalised anxiety disorder: British population study. ( 28473351 )
2017
19
Long noncoding RNA as an indicator differentiating schizophrenia from major depressive disorder and generalized anxiety disorder in nonpsychiatric hospital. ( 28092449 )
2017
20
Prefrontal and amygdala engagement during emotional reactivity and regulation in generalized anxiety disorder. ( 28501740 )
2017
21
Testing the metacognitive model against the benchmark CBT model of social anxiety disorder: Is it time to move beyond cognition? ( 28472176 )
2017
22
Transdiagnostic models of anxiety disorder: Theoretical and empirical underpinnings. ( 28450042 )
2017
23
Post-event processing in social anxiety disorder: Examining the mediating roles of positive metacognitive beliefs and perceptions of performance. ( 28088679 )
2017
24
On the context dependency of implicit self-esteem in social anxiety disorder. ( 28511035 )
2017
25
Childhood adversity, adult stress, and the risk of major depression or generalized anxiety disorder in US soldiers: a test of the stress sensitization hypothesis. ( 28443533 )
2017
26
Resting state functional connectivity in primary insomnia, generalized anxiety disorder and controls. ( 28500965 )
2017
27
Resting-state functional connectivity in generalized anxiety disorder and social anxiety disorder: Evidence for a dimensional approach. ( 28478685 )
2017
28
Generalized Anxiety Disorder, worry and attention to threat: A systematic review. ( 28448826 )
2017
29
Pharmacokinetic evaluation of pregabalin for the treatment of generalized anxiety disorder. ( 28075650 )
2017
30
Adult separation anxiety disorder in complicated grief: an exploratory study on frequency and correlates. ( 27683967 )
2017
31
The Association between Generalized Anxiety Disorder, Subthreshold Anxiety Symptoms and Fear of Falling among Older Adults: Preliminary Results from a Pilot Study. ( 28452660 )
2017
32
Impact of Comorbid Depressive Disorders on Subjective and Physiological Responses to Emotion in Generalized Anxiety Disorder. ( 27660375 )
2016
33
Working memory dysfunction associated with brain functional deficits and cellular metabolic changes in patients with generalized anxiety disorder. ( 27442922 )
2016
34
The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis. ( 27143896 )
2016
35
Factors related to the comorbidity between oppositional defiant disorder and anxiety disorders in preschool children. ( 27575516 )
2016
36
Diminished autonomic neurocardiac function in patients with generalized anxiety disorder. ( 27994467 )
2016
37
Cognitive and affective processing of social exclusion in borderline personality disorder and social anxiety disorder. ( 27616717 )
2016
38
Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone. ( 27486544 )
2016
39
Associations between compulsive buying and substance dependence/abuse, major depressive episodes, and generalized anxiety disorder among men and women. ( 27215919 )
2016
40
Cortical inhibitory and excitatory function in drug-naive generalized anxiety disorder. ( 28040450 )
2016
41
Autistic Traits and Symptoms of Social Anxiety are Differentially Related to Attention to Others' Eyes in Social Anxiety Disorder. ( 28000078 )
2016
42
Responsive Management of Early Resistance in Cognitive-Behavioral Therapy for Generalized Anxiety Disorder. ( 27031326 )
2016
43
Neurobiological Candidate Endophenotypes of Social Anxiety Disorder. ( 27593443 )
2016
44
An Underlying Common Factor, Influenced by Genetics and Unique Environment, Explains the Covariation Between Major Depressive Disorder, Generalized Anxiety Disorder, and Burnout: A Swedish Twin Study. ( 27620693 )
2016
45
"What I believe is true": Belief-confirming reasoning bias in social anxiety disorder. ( 27664816 )
2016
46
Serotonin synthesis rate and the tryptophan hydroxylase-2: G-703T polymorphism in social anxiety disorder. ( 27189957 )
2016
47
Development of social anxiety disorder secondary to attention deficit/hyperactivity disorder (the developmental hypothesis). ( 27585496 )
2016
48
Improvements in emotion regulation following repetitive transcranial magnetic stimulation for generalized anxiety disorder. ( 27467027 )
2016
49
A BRIEF ECOLOGICAL MOMENTARY INTERVENTION FOR GENERALIZED ANXIETY DISORDER: A RANDOMIZED CONTROLLED TRIAL OF THE WORRY OUTCOME JOURNAL. ( 27062682 )
2016
50
Major depressive disorder and generalized anxiety disorder show different autonomic dysregulations revealed by heart rate variability analysis in first onset drug-naA^ve patients without comorbidity. ( 27987241 )
2016

Variations for Anxiety Disorder

Copy number variations for Anxiety Disorder from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 139649 2 185171337 185512459 Deletion ZNF804A anxiety disorder

Expression for Anxiety Disorder

Search GEO for disease gene expression data for Anxiety Disorder.

Pathways for Anxiety Disorder

Pathways related to Anxiety Disorder according to GeneCards Suite gene sharing:

(show all 17)
id Super pathways Score Top Affiliating Genes
1
Show member pathways